FDA to consider faster approval process for life saving drugs
Under the new pathway, the FDA is expected to allow developers of such drugs to conduct smaller, faster clinical trials and provide a "special medical use" label enabling
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Activ-Blister desiccant film technology monitors the internal atmosphere of each individual blister cavity to safe guard moisture- and oxygen-sensitive solid-dose pharmaceuticals leading to product stability, increased shelf life